SEQUENTIAL ANTILYMPHOCTYE GLOBULIN/CYCLOSPORINE IMMUNOSUPPRESSION IN CADAVERIC RENAL TRANSPLANTATION. EFFECT OF DURATION OF ALG THERAPY
- 1 January 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 47 (1) , 96-101
- https://doi.org/10.1097/00007890-198901000-00022
Abstract
Recent studies have documented the efficacy of quadruple immunotherapy with sequential ALG/cyclosporine in cadaveric renal transplantation. However, the exact role of ALG in this regimen is controversial. Over a four-year period, we performed 429 cadaveric renal transplants (367 primary, 62 retransplants) with prednisone, azathioprine, and the sequential use of Minnesota antilymphoblast globulin (MALG) and CsA. ALG therapy was divided into three protocols: true sequential (n = 259, mean no. days of ALG = 8.2); extended (defined as sequential MALG/CsA continued for 14 days irrespective of renal function or CsA level, n = 103, mean no. days of ALG= 14.1); and therapeutic (continued MALG therapy for early breakthrough rejection, n = 67[15.6%], mean no. days of ALG = 17.2). The study groups were comparable and retrospectively analyzed in multivariate fashion for 15 variables. Requirement for postoperative dialysis was equivalent (14%) in both sequential and extended ALG groups. Extended ALG therapy failed to reduce the incidence of acute rejection (46.5% vs. 40.4% with true sequential therapy). Prolonging the duration of ALG treatment (>10 days) was associated with a higher risk of infection. Logistic regression analysis revealed that the use of OKT3 after ALG accountd for the higher infection rate. Duration of ALG therapy had no impact on patient or graft survival after a mean follow-up interval of 20 months. We recommended a quadruple immunosuppressive strategy in cadaveric renal transplantation with sequential MALG/CsA to minimize early allograft dysfunction and to achieve excellent patient and graft survival. MALG therapy should be stopped after renal functions documented and CsA levels are therapeutic. Further ALG therapy offers no immunologic advantage and may place the patient at high risk for infection if OKT3 rescue therapy is required.This publication has 10 references indexed in Scilit:
- INDIVIDUALIZATION OF IMMEDIATE POSTTRANSPLANT IMMUNOSUPPRESSIONTransplantation, 1988
- KIDNEY RETRANSPLANTATION IN THE CYCLOSPORINE ERA1Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, ILTransplantation, 1988
- SEQUENTIAL ANTILYMPHOBLAST GLOBULIN AND CYCLOSPORINE FOR RENAL TRANSPLANTATIONTransplantation, 1987
- THE EFFECTS OF DELAYED FUNCTION OF RECIPIENTS OF CADAVER RENAL ALLOGRAFTSTransplantation, 1986
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- MEDICAL RESEARCH COUNCIL TRIAL OF ANTILYMPHOCYTE GLOBULIN IN RENAL TRANSPLANTATIONTransplantation, 1983
- LOW-DOSE MAINTENANCE PREDNISONE AND ANTILYMPHOBLAST GLOBULIN FOR THE TREATMENT OF ACUTE REJECTIONTransplantation, 1983
- A CONTROLLED RANDOMIZED DOUBLE-BLIND STUDY OF ANTILYMPHOBLAST GLOBULIN IN CADAVER RENAL TRANSPLANTATIONTransplantation, 1983
- Biological effects of cyclosporin A: A new antilymphocytic agentInflammation Research, 1976
- USE OF HETEROLOGOUS ANTILYMPHOID AGENTS IN CANINE RENAL AND LIVER HOMOTRANSPLANTATION AND IN HUMAN RENAL HOMOTRANSPLANTATION1967